Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

Phase 3 Unknown 204 enrolled S.L.A. Pharma AG

RandomizedParallel-groupDouble-blindTreatment

Summary

2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.

Timeline

Start: 2018-12-05
Primary completion: 2024-06-30
Completion: 2024-07-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eicosapentaenoic acid free fatty acid	Unknown	1000 mg	—

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

Summary

Timeline

Drugs

Indications